{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:21:23Z","timestamp":1774074083861,"version":"3.50.1"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1164\/rccm.201710-2027le","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T16:59:45Z","timestamp":1510765185000},"page":"968-969","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Cooper\n                    <i>et al.<\/i>\n                    : The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease"],"prefix":"10.1093","volume":"197","author":[{"given":"Nicolas","family":"Roche","sequence":"first","affiliation":[{"name":"Paris Descartes University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Chapman","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[{"name":"Philipps-Universit\u00e4t Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix J. F.","family":"Herth","sequence":"additional","affiliation":[{"name":"German Center for Lung Research, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau","family":"Thach","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fogel","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-3914","authenticated-orcid":false,"given":"Petter","family":"Olsson","sequence":"additional","affiliation":[{"name":"Novartis Sverige AB, Taby, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patalano","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2026032023172255400_bib1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","article-title":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial","volume":"195","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023172255400_bib2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"key":"2026032023172255400_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"2026032023172255400_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026032023172255400_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"2026032023172255400_bib6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.rmed.2010.09.008","article-title":"Beclomethasone\/formoterol in the management of COPD: a randomised controlled trial","volume":"104","author":"Calverley","year":"2010","journal-title":"Respir Med"},{"key":"2026032023172255400_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/rccm.201705-0892LE","article-title":"What should be the cutoff value of blood eosinophilia as a predictor of inhaled corticosteroid responsiveness in patients with chronic obstructive pulmonary disease? [letter]","volume":"196","author":"Yilmaz","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023172255400_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1164\/rccm.201706-1105LE","article-title":"Reply: What should be the cutoff value of blood eosinophilia as a predictor of inhaled corticosteroid responsiveness in patients with chronic obstructive pulmonary disease? [letter]","volume":"196","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023172255400_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","article-title":"Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management","volume":"385","author":"Woodruff","year":"2015","journal-title":"Lancet"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/7\/968\/67122888\/ajrccm_197_7_968.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/7\/968\/67122888\/ajrccm_197_7_968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:17:32Z","timestamp":1774063052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/197\/7\/968\/8498654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201710-2027le","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,4,1]]}}}